The 36-month beta value for IRON is at 0.57. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IRON is 16.21M, and currently, shorts hold a 12.34% of that float. The average trading volume for IRON on July 03, 2024 was 457.08K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
IRON) stock’s latest price update
The stock of Disc Medicine Inc (NASDAQ: IRON) has decreased by -10.44 when compared to last closing price of 46.47.Despite this, the company has seen a loss of -6.49% in its stock price over the last five trading days. seekingalpha.com reported 2024-06-14 that Disc Medicine, Inc. released positive results from the phase 2 AURORA study, using bitopertin for the treatment of patients with EPP and XLP. Potential FDA feedback to initiate a pivotal study using bitopertin for the treatment of patients with EPP and XLP expected in the 2nd half of 2024. Results from the phase 1/2 study, using DISC-0974 for the treatment of patients with NDD-CKD, expected in the 2nd half of 2024.
IRON’s Market Performance
Disc Medicine Inc (IRON) has seen a -6.49% fall in stock performance for the week, with a 22.59% gain in the past month and a 29.92% surge in the past quarter. The volatility ratio for the week is 6.76%, and the volatility levels for the past 30 days are at 6.96% for IRON. The simple moving average for the past 20 days is 0.03% for IRON’s stock, with a -16.45% simple moving average for the past 200 days.
Analysts’ Opinion of IRON
Many brokerage firms have already submitted their reports for IRON stocks, with Raymond James repeating the rating for IRON by listing it as a “Outperform.” The predicted price for IRON in the upcoming period, according to Raymond James is $40 based on the research report published on April 01, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see IRON reach a price target of $65, previously predicting the price at $56. The rating they have provided for IRON stocks is “Equal-Weight” according to the report published on December 19th, 2023.
Raymond James gave a rating of “Strong Buy” to IRON, setting the target price at $75 in the report published on June 09th of the previous year.
IRON Trading at 18.85% from the 50-Day Moving Average
After a stumble in the market that brought IRON to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.37% of loss for the given period.
Volatility was left at 6.96%, however, over the last 30 days, the volatility rate increased by 6.76%, as shares surge +14.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +45.07% upper at present.
During the last 5 trading sessions, IRON fell by -6.49%, which changed the moving average for the period of 200-days by -21.22% in comparison to the 20-day moving average, which settled at $41.87. In addition, Disc Medicine Inc saw -27.94% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IRON starting from Bitterman Kevin, who purchase 222,223 shares at the price of $36.00 back on Jun 17 ’24. After this action, Bitterman Kevin now owns 420,549 shares of Disc Medicine Inc, valued at $8,000,028 using the latest closing price.
Ashiya Mona, the Director of Disc Medicine Inc, purchase 83,334 shares at $36.00 during a trade that took place back on Jun 17 ’24, which means that Ashiya Mona is holding 941,569 shares at $3,000,024 based on the most recent closing price.
Stock Fundamentals for IRON
The total capital return value is set at -0.29. Equity return is now at value -28.23, with -26.96 for asset returns.
Based on Disc Medicine Inc (IRON), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -35.34.
Currently, EBITDA for the company is -91.03 million with net debt to EBITDA at 3.55. The liquidity ratio also appears to be rather interesting for investors as it stands at 23.70.
Conclusion
In conclusion, Disc Medicine Inc (IRON) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
